Parabilis Medicines
Cambridge, Massachusetts, United States · Biopharma, Biotechnology, Health Care · 170 employees
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blo
Funding history
- Series A — $75.0M — Jun 2026
- Post-IPO Equity — $450.0M — Jun 2026
- Series F — $305.0M — Jan 2026
Recent signals
- Jun 09, 2026: Raised $75.0M in Series A
- Jun 06, 2026: Raised $450.0M in Post-IPO Equity
- Jan 08, 2026: Raised $305.0M in Series F
- Sep 03, 2025: Parabilis Medicines Appoints Fawzi Benzaghou as Chief Medical Officer
- Oct 28, 2024: Launched Parabilis Medicines Announces Corporate Name Change and Unveils Helicon Platform for Drug Discovery
See plans & pricing → Track Parabilis Medicines’s funding, hiring, and signals — with verified contacts — on Fundz.